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Abstract 
Background: Cisplatin is a popular antineoplastic agent used to treat cervical cancer in women from low and 
middle-income countries. Cisplatin treatment is associated with ototoxicity, often resulting in hearing loss. In light 
of this, it is crucial to conduct baseline audiological assessments prior to treatment initiation in order to evaluate the 
extent of cisplatin-associated-ototoxicity. Additionally, the identification of inherent risk factors and hearing patterns 
in specific patient cohorts is needed, especially in South Africa, a middle-income country characterized by the quad-
ruple burden of disease (Human Immunodeficiency Virus (HIV), Tuberculosis (TB), Diabetes and Hypertension).
Methods: This study aimed to describe a profile of risk factors and hearing in a cohort of females with cervical cancer 
before cisplatin treatment commenced. A descriptive study design that included 82 cervical cancer patients, who 
underwent audiological evaluation prescribed for ototoxicity monitoring was conducted.
Results: All participants (n = 82) presented with risk factors (diabetes, hypertension, HIV, and antiretroviral therapy) 
for cisplatin ototoxicity and/or pre-existing sensorineural hearing loss. High-frequency tinnitus was the most common 
otological symptom experienced by 25 (31%) participants. Fifty-nine (72%) participants presented with normal hear-
ing, twenty-two (27%) with a sensorineural hearing loss, and 36% were diagnosed with mild hearing loss. Abnormal 
Distortion Product Otoacoustic Emissions (DPOAE) findings were obtained bilaterally in two participants (2.4%), in the 
right ear only of another two (2.4%) participants and the left ear of three participants (3.7%). Most participants (94%) 
had excellent word recognition scores, demonstrating an excellent ability to recognize words within normal conver-
sational levels under optimal listening conditions. Age was significantly associated with hearing loss at all thresholds. 
Among the co-morbidities, an HIV positive status significantly triggered hearing loss, especially at higher frequencies.
Conclusion: This study demonstrated that South African females with cervical cancer present with various co-mor-
bidities, which may predispose them to develop cisplatin-associated -ototoxic hearing loss. Identification of these co-
morbidities and hearing loss is essential for the accurate monitoring of cisplatin toxicities. Appropriate management 
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Background
Hearing loss has now been identified as the fourth high-
est cause of disability globally, with South Asian, Asia 
Pacific, and Sub-Saharan African regions being the most 
affected. This is evident by prevalence rates being almost 
four times higher in low-income compared to high-
income regions [1]. While the aging population is one 
of the main contributors to this high prevalence, others 
include noise exposure (occupational and recreational), 
chronic ear infections, and ototoxicity [1]. With hearing 
loss being on the increase globally, the role of the audi-
ologist in the early identification, diagnosis, and manage-
ment of this “invisible condition” cannot be overstated. In 
an attempt to provide the best possible management for 
hearing loss, audiologists must have a clear understand-
ing of audiological patterns affecting specific patient 
populations, through audiological profiling. As both 
occupational noise exposure and ototoxicity often result 
in progressive, permanent hearing loss, audiological 
monitoring for early identification is essential to audio-
logical service delivery [1]. In any audiological monitor-
ing program, the purpose of the baseline audiological 
assessment is to document the individual’s hearing sta-
tus before exposure to the noxious agent (either ototoxic 
drug or noise) [2]. While the effects of noise exposure are 
reduced or avoidable through the use of hearing protec-
tion devices, ototoxicity, on the other hand, is unavoid-
able. Ototoxicity results from exposure to ototoxic drugs, 
which are often the drug treatments used to treat vari-
ous conditions such as Human Immunodeficiency Virus 
(HIV), tuberculosis (TB), and cancer [3].
Females with cervical cancer are identified as an “at-
risk” cohort for ototoxicity in South Africa. It is the sec-
ond most common cancer diagnosed in women in South 
Africa, with an age-standardized incidence rate of 26.96 
per 100,000. Additionally, 1 in 35 women presents with 
a lifetime risk (0–74 years) of developing cervical cancer 
[4] coupled with late stage of diagnosis [5], resulting in 
treatments mainly confined to brachytherapy and cispl-
atin-containing-chemotherapy [6].
Cisplatin is a popular and effective antineoplastic drug 
used in the treatment of many cancer types, including 
cervical cancer; however, it is well-known for its ototoxic 
side effects [7]. The latter is due to the structures of the 
inner ear being susceptible to damage, and the outer hair 
cells in the basal turn of the cochlea being most affected 
[8]. The manifestation of cisplatin-induced-ototoxicity is 
high-frequency, progressive sensorineural hearing loss 
[9], which is often accompanied by tinnitus [10].
Further complicating the situation for women with cer-
vical cancer is their diagnosis of HIV, which requires the 
concomitant use of antiretroviral therapy (ARTs). This is 
problematic since cervical cancer is regarded as an AIDS-
defining illness, and HIV in itself, has been reported to 
cause hearing loss [11]. Proposed underlying mecha-
nisms include the direct action of the virus on the central 
nervous system, including the  8th nerve, or opportunis-
tic infections associated with hearing loss [11]. Further-
more, ARTs are also reported to negatively affect hearing 
[12]. As a result, patients who are HIV positive and also 
have cervical cancer are a high-risk cohort for hearing 
loss, as there is likely to be an additive adverse effect on 
their hearing. Evidence shows that age [13, 14], cumula-
tive dose [15, 16]¸ exposure to concomitant noise [17], 
chemicals and other ototoxic medications [16], as well as 
pre-exposure hearing ability [16], are known risk factors 
which may increase the severity of cisplatin ototoxicity.
Further complicating this disease profile is the increas-
ing incidence of non-communicable diseases (NCDs) 
[18], including type 2 diabetes and hypertension [19], 
which are more prevalent than the country’s BRICS 
counterparts, i.e., Brazil, Russia, India, and China [20]. 
Therefore, there is an increased likelihood of cervical 
cancer patients presenting with other co-morbidities, 
which may also have an impact on hearing abilities, as 
individuals with diabetes[21] and hypertension [22] have 
also been found to present with reduced hearing sensitiv-
ity at all frequencies.
Given the potential for combined co-morbidities, and 
the resultant exposure to ototoxic medication, the need 
for baseline audiological monitoring is pivotal to pro-
vide a frame of reference for future audiometric test-
ing in complex disease profiles. Determining changes in 
hearing ability over time will significantly contribute to 
a better understanding of the associated risk character-
istics as well as identify how hearing loss manifests in 
complex disease profiles before cisplatin chemotherapy. 
Furthermore, obtaining baseline audiometric results may 
prevent misinterpretation of high-frequency hearing loss 
when monitoring cisplatin ototoxicity, since presbycusis 
(hearing loss due to age) may mimic the configuration of 
cisplatin ototoxicity, as both manifest in a high-frequency 
of these patients is pivotal to reduce the adverse effects that hearing impairment can have on an individual’s quality 
of life and to facilitate informed decision-making regarding the commencement of cisplatin chemotherapy.
Keywords: Cisplatin ototoxicity, Cervical cancer, Diabetes, Hearing, HIV, Hypertension, Ototoxic medication, Risk 
factors
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sensorineural hearing loss [23]. Additionally, knowledge 
of individual risk and audiological profiles before treat-
ment allows for accurate audiological monitoring of the 
effect of cisplatin. However, there needs to be due con-
sideration of co-morbid conditions and confounding 
variables, of which many studies [15, 24–27] investigat-
ing hearing loss, to date, have failed to consider. This 
paper reports on the baseline audiological characteristics 
amongst patients with cervical cancer and reports on 
associated risk factors and confounding variables. Fur-
thermore, we provide recommendations to implement 




Findings reported in this paper form part of a prospec-
tive cohort study among cervical cancer patients before 
cisplatin exposure.
Setting
The study was conducted at a referral hospital offering 
tertiary services in KwaZulu-Natal (KZN), South Africa, 
as defined in the regulations relating to categories of hos-
pitals [28]. This site was selected as it provides regional 
services to an approximate population of 1 million and 
tertiary services (highly specialized health care) to the 
Western half of KZN, i.e., five health districts with a total 
population of 3.5 million. It is also one of the main refer-
ral centers for cancer patients and houses an audiology 
department.
Study sample
Patients attending the hospital’s oncology clinic who met 
all the inclusion criteria were identified, informed of the 
study and subsequently invited to participate by the clini-
cians, nurses as well as the primary investigator. Of the 
86 patients who responded to the invitation, 82 adult 
females (≥ 18  years) with a diagnosis of cervical cancer 
were recruited before the commencement of the first 
cycle of cisplatin-based chemotherapy. Patients present-
ing with profound hearing loss at baseline assessment, 
or those who had previously received cisplatin chemo-
therapy or had a history of medical conditions such as 
tuberculosis, and malaria were excluded. Four of the 86 
patients were excluded, as one had previously received 
chemotherapy, while the other three were treated with 
aminoglycoside antibiotics following a diagnosis of multi-
drug resistant tuberculosis (MDR TB). All participants 
were tested for HIV, and those who were diagnosed as 
being HIV positive received antiretroviral therapy as part 
of the clinical management.
Data collection
Following written informed consent, participants’ medi-
cal records were reviewed. Additionally, a structured 
questionnaire (Additional file 1) was used to solicit infor-
mation on self-reported symptoms indicative of hearing 
loss, hearing history, medical history, family history of 
hearing loss, and history of noise exposure[29]. Audio-
logical assessments were conducted on each participant 
following the review of the medical file. These assess-
ments included otoscopy, tympanometry, ipsilateral and 
contralateral acoustic reflex threshold testing, pure tone 
air and bone conduction audiometry, extended high-
frequency audiometry, speech reception threshold (SRT) 
testing, word recognition score (WRS) testing and dis-
tortion product otoacoustic emission (DPOAE) test-
ing, consistent with the ototoxicity monitoring protocol, 
as prescribed by American Speech-Language-Hearing 
Association (ASHA) (1994) [2], and Health Professions 
Council of South Africa (HPCSA) (2018) [30]. A table 
reflecting the audiological procedures, motivation for 
its use, and the equipment utilized is presented in Addi-
tional file 2.
Data analysis
Data is described using frequencies, percentages, medi-
ans, and ranges. The distribution of participant’s pure-
tone air conduction thresholds (PTACT) at the different 
frequencies was analyzed separately for the left and right 
ear. Risk factor information was gathered from patients’ 
self-reports and medical records and was stratified into 
two risk categories (low-risk category ≤ two risk factors; 
high-risk ≥ three risk factors). The results of the audio-
logical assessment were analyzed as per normative data 
indicated in Additional file 3.
The Tobit (censored) regression was used to estimate 
the linear relationship between hearing loss and risk fac-
tors, adjusted for age, as it accounted for non-responses 
(values above the limits of the audiometer, as indicated 
in Additional file 4) at the various pure tone frequencies. 
Methods that consider non-responses as actual values 
usually bias the estimate of the coefficients leading to 
incorrect conclusions. All statistical analyses were con-
ducted using SAS 9.4 (Johannesburg, SA).
Reliability and validity
The reliability of results was ensured by using all standard 
audiological tests and procedures to ensure consistency. 
Case history ascertainment was confirmed by reviewing 
medical records. The cross-check principle was employed 
during audiological evaluations. All equipment was cali-
brated by a qualified technician annually, in accordance 
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with the South African National Standards set by the 
South African Bureau of Standards (SABS) with daily 
biological checks conducted by the primary researcher.
Results
Descriptive analysis
Data from 82 female patients with cervical cancer were 
analyzed, and the demographic and medical character-
istics are summarized in Table 1. The median age of the 
cohort was 52 years (range 32–79 years). Furthermore, 37 
(45.1%) participants presented with stage IIB, 29 (35.4%) 
presented with stage IIIB cervical cancer, whereas stage 
IA, IB, and IIIA were less common (less than 4% each). 
Sixty-eight participants (82.9%) presented with co-
morbidities, of which 44 (64.7%) were HIV positive and 
on ARTs. The 5 patients with stage 1 cancer received 
chemotherapy either due to peri-neural involvement on 
histology, lymph node involvement post-surgery, whilst 
another developed a local recurrence post-hysterectomy.
A summary of the self-reported audiological symp-
toms is presented in Table 2. Firstly, nine (11.0%) partici-
pants reported reduced hearing sensitivity, of which five 
(55.6%) were bilateral. Tinnitus was the most common 
self-reported symptom experienced by 28 participants 
(34.0%), with 25 of these participants (89.3%) describing 
the tinnitus as high-frequency in nature. Only two par-
ticipants (2.4%) reported repeated ear infections.
Abnormal otoscopic findings (in this case, tympanic 
membrane perforation) were evident in the right ear of 
one participant (1.0%), and the left ear of another par-
ticipant (1.0%). Tympanometric findings revealed nor-
mal results, i.e., Type A tympanograms in 81 (98.8%) 
participants bilaterally. Acoustic reflex threshold testing 
revealed abnormalities in the right ear of 33 participants 
(40.0%) and the left ear of 38 participants (46.0%).
Moreover, hearing loss was identified in the right ear of 
five participants (6.0%) in the left ear of six participants 
(7.0%) and bilaterally in 17 participants (21.0%). Of the 
participants with bilateral hearing loss, five (17.0%) had 
indicated reduced hearing sensitivity. Among those par-
ticipants with bilateral hearing loss (n = 17), five (17.0%) 
reported experiencing tinnitus. Complaints of tinnitus 
were also reported by two (33.3%) of the six participants 
with hearing loss in the left ear only and two (28.7%) of 
the seven participants with hearing loss in the right ear 
only. Mixed hearing loss was identified in the right ear 
of one participant and the left ear of another, with the 
remaining participants presenting with sensorineu-
ral hearing loss. Mild hearing loss was most common 
(35.0%), followed closely by mild-moderate, and this pat-
tern was evident bilaterally.
A steady decline in the number of participants with 
hearing thresholds between -10 and 25  dB was seen 
as the frequency increased, as indicated in Fig.  1. Con-
versely, the number of participants with no responses 
steadily increased as the frequency increased. Abnor-
mal DPOAE findings were obtained bilaterally in two 
Table 1 Demographic and medical characteristics of the 




 <  = 39 11 (13.4)
40–49 25 (30.5)
50–59 25 (30.5)
 >  = 60 21 (25.6)
Total 82
Ethnic group





I A 3 (3.7)
I B 2 (2.4)
II A 9 (10.9)
II B 37 (45.1)
III A 2 (2.4)





Table 2 Self- reported audiological symptoms at baseline
Symptoms n (%)
Reduced hearing sensitivity 9 (11%)






Aural fullness 4 (4.9)
Tinnitus 28 (34)




Description of tinnitus (n = 28) High frequency-25 (89.3)
Low frequency-2 (7.1)
Pulsating-1 (3.6)
Repeated middle ear infections 2 (2.4)
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participants (2.4%), in the right ear only of another two 
(2.4%) participants and the left ear only of another three 
participants (3.7%).
Additionally, the speech reception threshold (SRT) 
testing revealed good SRT-PTA correlation in more than 
95% of the participants bilaterally; thus, confirming the 
validity of pure-tone test results. Word recognition score 
testing showed that most participants had an excellent 
ability to understand speech within normal conversa-
tional levels under optimal listening conditions.
Moreover, 73 (89%) participants presented with one or 
more risk factors for hearing loss, as indicated in Table 3. 
Fourteen of the 18 participants (77.8%), categorized as 
high risk, were HIV positive.





















Frequency distribuon of paents' PTACT within various intensity ranges at
different frequencies (Le ear)





















Frequency distribuon of paents' PTACT within various 
intensity ranges at different frequencies (Right ear) 
 -10 to 15dB 16 to 25dB 26 to 40dB 41 to 55dB 56 to 70dB 71 to 90dB >90dB No response
Fig. 1 Percent distribution of participants’ PTACT within the various intensity ranges at the different frequencies for the left and right ear
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Additionally, simple and multiple Tobit regressions 
were fitted to test the association between the hear-
ing loss at various frequencies and covariates such as 
age, HIV status, NCDs (hypertension, diabetes co-
morbidities), and use of ototoxic medication. All HIV 
positive patients took ototoxic medication, support-
ing a significant correlation (p < 0.0001) between HIV 
status and the use of ototoxic medication. Hence, we 
excluded the use of ototoxic medication to avoid the 
multi-collinearity problem. Age, being a confounding 
variable, was accounted for in the multiple regression 
model. Results of simple and multiple regression mod-
els are depicted in Tables 4 and 5 for the right ear and 
Tables 6 and 7 for the left ear, respectively. In the sim-
ple Tobit regression, age was found to be a significant 
predictor of thresholds at all (low to extended high) fre-
quencies (Table  4, 6). The direction of the association 
Table 3 Overview of the study population
















0 9 0 0 0 0 0
1 12 2 5 0 0 5
2 43 2 13 30 31 10
3 16 4 8 12 12 12
4 1 1 1 1 1 0
5 1 1 1 1 1 1
Table 4 Simple Tobit regression (right ear)
A positive coefficient of an estimate indicates that the mean of hearing loss increase with the value of the potential risk factor. The higher the estimate the higher the 
hearing loss
Reference categories: HIV = 0 and NCD (Hypertension and Diabetes) = 0
LFPTT, Low-frequency pure tone thresholds; MFPTT, Mid-frequency pure tone thresholds, HFPTT, High frequency pure tone thresholds; EHFPTT Extended high-
frequency pure tone thresholds
Frequency (Hz) No. of non-responses Risk factors
Estimate of coefficient (SE); p-value
Age HIV Seropositive NCD
LFPTT
125 0 0.2 (0.09); 0.02 1.15 (1.98); 0.56 2.33 (2.16); 0.28
250 0 0.26 (0.1); 0.01 3.8 (2.24); 0.09 − 0.42 (2.58); 0.87
500 0 0.25 (0.1); 0.01 5.89 (2.23); 0.01 − 0.46 (2.66); 0.86
MFPTT
1000 1 0.11 (0.12); 0.38 3.52 (2.68); 0.19 − 2.52 (3.08); 0.41
2000 0 0.32 (0.13); 0.01 3.33 (3.04); 0.27 − 0.3 (3.54); 0.93
HFPTT
4000 0 0.56 (0.14); 0.01 8.21 (3.2); 0.01 1.0 (3.71); 0.79
8000 0 0.86 (0.17); 0.01 10.97 (4.02); 0.01 3.21 (4.6); 0.48
9000 0 1.13 (0.17); 0.01 11.4 (4.51); 0.01 4.37 (5.17); 0.39
EHFPTT
10,000 1 1.29 (0.19); 0.01 14.41 (4.97); 0.01 2.64 (5.83); 0.65
11,200 1 1.37 (0.20); 0.01 16.90 (5.25); 0.01 3 (6.17); 0.63
12,500 12 (14.6%) 1.79 (0.21); 0.01 21.57 (5.78); 0.01 − 5.45 (6.92); 0.43
14,000 31 (37.8%) 2.04 (0.27); 0.01 24.62 (6.63); 0.01 − 3.95 (7.88); 0.62
16,000 57 (70%) 1.64 (0.34); 0.01 22.16 (7.06); 0.01 − 5.1 (6.85); 0.46
18,000 75 (91%) 0.47 (0.22); 0.03 5.31 (3.84); 0.17 1.06 (2.92); 0.72
20,000 79 (96%) 0.42 (0.51); 0.14 8.7 (0.88); 0.01 − 0.95 (1.23); 0.44
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is positive, indicating that the older the patient, the 
higher the risk of hearing loss.
Similarly, HIV status was predictive at high and 
extended high-frequency thresholds in the simple Tobit 
regression. The percentage of non-responses was very 
high at frequencies of 16 kHz, 18 kHz, and 20 kHz. This 
ranged from 70 to 96% for the right ear and from 61 to 
89% for the left ear, respectively. Hence, we did not inter-
pret results at these frequencies, as interpreting informa-
tion obtained from a small sample is unreliable.
Discussion
In this study, we report for the first time novel findings 
on baseline audiological profiles and risk factors, which 
may further exacerbate hearing loss in patients with cer-
vical cancer, a cohort already at risk of reduced quality of 
life. Cervical cancer is the second most common cancer 
among females in the African continent, including South 
Africa [31], which is also burdened with a high preva-
lence of infectious and NCDs [20]. We report that 89% 
of the participants in the current study presented with 
co-morbid conditions (HIV, diabetes, and hypertension), 
as reflected by the risk profile. A multitude of risk factors 
can profoundly decrease the quality of life of these par-
ticipants. Consequently, it becomes critically important 
that the medical and rehabilitation fraternity consider the 
patient’s quality of life, especially since more people with 
chronic conditions and compromised immune systems 
are living longer, due to greater access to treatments. In 
light of this, we need to acknowledge the risk profile of 
these cervical cancer patients receiving cisplatin and 
understand the depth to which hearing loss may impinge 
on this cohort by either prevention and/or treatment in 
order to avoid further increasing the risk for hearing loss 
and compromising the quality of life.
Acknowledging the risk profile may also result in a 
greater realization of the complexity of the synergis-
tic effects of these risk factors for cisplatin ototoxicity. 
Simultaneous exposure to multiple risk factors (co-mor-
bidities and ototoxic medication) can potentiate auditory 
dysfunction that is greater than the sum of each insult 
given individually, implying a synergistic effect [32]. 
In agreement, an in  vivo model by Bielefeld et  al. dem-
onstrated an additive effect of cisplatin and increasing 
age on the cochlear [33]. Additionally, a study by Grat-
ton et  al. [17] showed that the combination of cisplatin 
and moderate-to-high levels of noise caused significantly 
more hair cell damage as well as hearing loss at the higher 
frequencies compared to either noise or cisplatin alone. 
While each of the changes may present clinically or audi-
ologically differently, they often combine and result in a 
bilateral mild to moderate mid to high-frequency senso-
rineural hearing loss [34]. The effects of aging on hear-
ing sensitivity could be worsened by the use of certain 
ARTs as a result of mitochondrial toxicity, which results 
in accelerated changes in the cochlear and/or central 
auditory system [35]. This may be plausible in the current 
study, as there is a high prevalence of HIV positive cases 
(53.7%) in this cohort.
Furthermore, if a person presents with more than 
one of these medical conditions, i.e., diabetes, hyper-
tension, and/or HIV as they age, there is likely to be an 
even greater antagonistic, additive effect on hearing that 
may progressively worsen during the course of cisplatin 
chemotherapy. This, therefore, reinforces the importance 
of the audiologist conducting a detailed case history at 
baseline so that they may be able to identify probable rea-
sons for the otological symptoms experienced as well as 
the audiological profile of the patient.
A review of the audiological profile at baseline revealed 
high-frequency tinnitus to be the most common self-
reported otological symptom. While tinnitus is often 
associated with a hearing loss, the number of participants 
with self-reported hearing difficulties and even those with 
clinical hearing loss was lower than the complaints of tin-
nitus in our study. This finding should be of no surprise, 
Table 5 Multiple Tobit regression adjusting for age (right ear)
LFPTT, Low-frequency pure tone thresholds; MFPTT, Mid-frequency pure tone 
thresholds; HFPTT, High frequency pure tone thresholds; EHFPTT, Extended 












125 0 0.79 (2.78); 0.77 2.42 (2.13); 0.26
250 0 1.72 (3.26); 0.59 − 0.01 (2.50); 0.99
500 0 4.17 (4.02); 0.3 0.26 (2.56); 0.92
MFPTT
1000 1 3.52 (2.68); 0.19 − 2.52 (3.08); 0.41
2000 0 1.81 (4.52); 0.69 − 0.17 (3.46); 0.96
HFPTT
4000 0 1.93 (3.2); 0.67 1.70 (3.42); 0.62
8000 0 1.07 (5.15); 0.83 3.93 (3.94); 0.32
9000 0 4.18 (5.32); 0.43 5.06 (4.07); 0.21
EHFPTT
10,000 1 5.51 (5.84); 0.34 3.32 (4.47);  0.46
11,200 1 4.40 (6.21); 0.01 3.88 (4.76); 0.41
12,500 12 (14.6%) 8.32 (6.02); 0.16 − 5.96 (4.54); 0.38
14,000 31 (37.8%) 6.42 (6.79); 0.34 − 0.49 (5.33); 0.93
16,000 57 (70%) 0.99 (7.71); 0.89 0.76 (6.0); 0.89
18,000 75 (91%) 0.03 (3.45); 0.99 3.53 (2.99); 0.24
20,000 79 (96%) 9.58 (4.08); 0.02 − 0.26 (0.48); 0.59
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taking into consideration that most participants pre-
sented with other medical conditions, namely diabetes, 
hypertension, and HIV, and its associated treatments of 
which has been reported to cause tinnitus as a side effect 
[3]. These findings are in agreement with Shargorodsky 
et al. [36], who reported the prevalence of tinnitus to be 
25.3% in a sample of the general population in the United 
States of America. Furthermore, we report that seven of 
the participants with hearing loss also complained of tin-
nitus, an early indicator of auditory dysfunction [37].
Complaints of otalgia appeared to be much lower than 
expected (6%) when compared to previous literature 
focusing on HIV infected participants in South Africa, 
which indicated that 19% of the sample reported otalgia 
[11]. It is, however, in agreement with the findings of Tuz 
et  al., who reported that otalgia was experienced by 8% 
of their control group participants [38]. Otalgia may be a 
result of pain within the ear or ‘referred pain,’ i.e., due to 
pain in structures around the ear or other head and neck 
structures [39]. With only two patients reporting a his-
tory of ear infections and two displaying abnormalities 
on otoscopic examination and tympanometry, the otalgia 
could likely be attributed to these clinical findings.
The small number of participants presenting with 
a history of ear infections and/or otoscopic and 
tympanometric abnormalities is a rare contradictory 
finding because more than 50% of the current study par-
ticipants are HIV positive and previous reports otitis 
media to be most common in this population [40, 41]. 
However, this finding could be attributed to the fact that 
all participants diagnosed with HIV were receiving ARTs. 
While the duration of treatment with ARTs is unknown, 
it can be speculated that it is longer than a period of six 
months as patients generally commenced with treat-
ment no earlier than six months after being diagnosed 
with cervical cancer, which would have prompted an HIV 
diagnostic test and the subsequent treatment with ARTs. 
The use of ARTs has proven to significantly improve the 
functioning of the immune system of HIV infected indi-
viduals, which indirectly results in less frequent middle 
ear abnormalities such as otitis media [11].
The percentage of participants with hearing loss (27%) 
at baseline in this current study is in agreement with 
Nagy et  al., who reported that 26% of the study sample 
presented with hearing abnormalities [23]. The number 
of complaints of difficulty hearing was much lower com-
pared to the audiological assessment, indicating that 
participants may have gradually adjusted to the reduced 
hearing sensitivity due to the loss being gradual in nature. 
This is generally seen in presbycusis and is consistent 
Table 6 Simple Tobit regression (left ear)
LFPTT, Low frequency pure tone thresholds; MFPTT, Mid frequency pure tone thresholds; HFPTT, High frequency pure tone thresholds; EHFPTT, Extended high 
frequency pure tone thresholds; NCD, Hypertension and Diabetes
Frequency (Hz) No. of non-responses Variables
Estimate of coefficient (SE); p-value
Age HIV seropositive NCD
LFPTT
125 1 0.36 (0.12); 0.01 0.95 (2.77); 0.73 3.51 (3.14 (0.26)
250 0 0.41 (0.13); 0.01 0.71 (3.04); 0.82 3.5 (3.42); 0.31
500 0 0.4 (0.14); 0.01 0.36 (3.28); 0.91 4 (3.76); 0.28
MFPTT
1000 0 0.42 (0.16); 0.01 0.88 (3.56); 0.8 3.21 (4.02); 0.42
2000 0 0.55 (0.16); 0.01 2.21 (3.66); 0.55 3.25 (4.11); 0.43
HFPTT
4000 1 0.91 (0.17); 0.01 7.14 (4.29); 0.09 7.26 (4.89); 0.14
8000 0 1.11 (0.2); 0.01 9.77 (5.07); 0.05 1.62 (5.77); 0.01
9000 1 1.33 (0.19); 0.01 16.11 (4.92); 0.001 4.13 (5.82); 0.48
EHFPTT
10,000 3 1.64 (0.19); 0.01 21.23 (5.28); 0.01 5.25 (6.58); 0.42
11,200 5 1.95 (0.19); 0.01 25.3 (5.61); 0.01 0.54 (7.15); 0.94
12,500 12 (14.6%) 2.02 (0.19); 0.01 26.4 (5.76); 0.01 − 1.81 (7.36); 0.81
14,000 23 (28%) 1.85 (0.21); 0.01 22.37 (5.76); 0.01 4.38 (7.16); 0.54
16,000 50 (61%) 0.92 (0.23); 0.01 12.93 (4.81); 0.01 6.87 (5.67); 0.22
18,000 68 (83%) 0.71 (0.46); 0.13 6.1 (9.42); 0.52 11.85 (9.62); 0.22
20,000 73 (89%) 0.23 (0.21); 0.26 1.81 (4.34);0.68 4.74 (4.99);0.34
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with the age characteristics of our study population. 
Additionally, literature reports that hearing loss is usu-
ally only suspected or detected when communication dif-
ficulties become evident [42], and may go unnoticed in 
the case of mild hearing loss, as evident in the current 
study, with mild hearing loss being the most common 
bilaterally.
Furthermore, if the extended high-frequency audiom-
etry thresholds were considered in the general classifi-
cation of hearing loss, more participants would likely be 
presenting with hearing loss. However, due to the lack of 
consensus around normative data for the extended fre-
quency range, none of the classification systems for hear-
ing loss consider this frequency range. Consequently, this 
data was merely used in this baseline study to reflect that 
the audiometric patterns were of a sloping configuration. 
The sloping configuration of the audiological patterns is 
congruent with other test findings and the demographic 
and medical profile of the participants. These findings are 
in agreement with previous reports, as with increasing 
age [43], hypertension [22], diabetes [44], HIV [41], and 
the use of ototoxic medication [3], a high-frequency sen-
sorineural hearing loss is initially evident.
The highly limited occurrence of conductive hearing 
loss is in agreement with other South African studies [11, 
45, 46]. The higher percentage of individuals presenting 
with sensorineural hearing loss (96%) may be explained 
by the fact that more than 60% of participants were HIV 
positive currently being treated with ARTs, which are 
considered ototoxic [3]. Additionally, other co-morbid-
ities, including diabetes and/or hypertension [22, 45, 
47–49], as well as aging [43], are all well-known to affect 
cochlear functioning, which consequently results in sen-
sorineural hearing loss. Hence, indicating that this cohort 
of participants is at a higher risk for permanent hearing 
loss.
Due to the sensorineural nature of the hearing loss, 
one would expect most of these participants to present 
with reduced or absent DPOAEs. DPOAEs are generally 
absent in frequency regions with pure tone thresholds 
greater than 50  dB [50]. Therefore, with most partici-
pants in the study presenting with normal hearing or 
mild degrees of hearing loss, it is likely that these individ-
uals may have presented with DPOAE amplitudes greater 
than 6 dB at four or more of the DPOAE test frequencies, 
resulting in the DPOAE result being considered as nor-
mal, as is seen in the current study.
Most participants presenting with normal hearing 
or mild degrees of hearing loss may also account for 
the excellent word recognition scores. This, therefore, 
corroborates with the small number of participants 
self-reporting hearing difficulties. Our findings are in 
agreement with that of Sooy [51], who also reported word 
recognition scores above 82%, with the majority of par-
ticipants obtaining scores above 90% despite presenting 
with abnormal audiological findings. It may, therefore, be 
necessary to include speech in noise tests during baseline 
evaluations to stress the auditory system by portraying a 
‘real world’ scenario. While impaired word recognition 
scores were expected, the results of this assessment may 
have been influenced by the use of monitored live voice 
testing and speech tests that have not been standardized 
for isiZulu speaking individuals, which comprised more 
than 90% of the cohort. Despite the many disadvantages 
of monitored live voice testing [52], this method of pres-
entation was utilized due to the lack of the necessary 
equipment at the study site, a common issue affecting 
many institutions in low and middle-income countries.
Furthermore, due to the absence of a validated speech 
wordlist for isiZulu speakers, a decision was taken to uti-
lize the Digits test for speech recognition threshold test-
ing [53] and a speech word list which is routinely used 
in KZN hospitals. As the validity of this speech word 
list has not been established, it is likely that this tool 
Table 7 Multiple Tobit regression adjusting for age and 
co-morbidities (left ear)
LFPTT, Low-frequency pure tone thresholds; MFPTT, Mid-frequency pure tone 
thresholds; HFPTT, High-frequency pure tone thresholds; EHFPTT, Extended 












125 1 11.59 (3.69); 0.01 2.72 (2.81); 0.33
250 0 9.59 (4.11); 0.02 2.93 (3.14); 0.35
500 0 9.66 (4.6); 0.04 3.42 (3.52); 0.33
MFPTT
1000 0 6.74 (5.05); 0.18 2.91 (3.86); 0.45
2000 0 7.65 (4.98); 0.12 2.99 (3.81); 0.43
HFPTT
4000 1 9.68 (5.36); 0.07 7.19 (4.09); 0.08
8000 0 6.5 (6.37); 0.31 2.03 (4.87); 0.68
9000 1 1.02 (5.93); 0.86 5.29 (4.51); 0.24
EHFPTT
10,000 3 0.07 (6.18); 0.99 6.73 (4.68); 0.15
11,200 5 0.90 (6.0); 0.88 2.11 (4.55); 0.64
12,500 12 (14.6%) 2.87 (5.84)0.62 − 0.68 (4.42); 0.88
14,000 23 (28%) 8.25 (6.21); 0.18 6.11 (4.72); 0.19
16,000 50 (61%) − 1.3 (6.76); 0.85 11.35 (5.54); 0.04
18,000 68 (83%) 5.68 (12.71); 0.65 15.23 (10.54); 0.15
20,000 73 (89%) 1.75 (5.92); 0.77 5.56 (5.16); 0.28
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may not adequately stress the auditory system to allow 
for an accurate description of the individuals’ ability to 
recognize speech and should, therefore, be viewed with 
caution. However, despite word recognition scores not 
being severely compromised, and most participants not 
presenting with debilitating degrees of hearing loss at 
this stage, they would still require counseling. Audiolo-
gists should still counsel their patients about the effects 
of concomitant exposure to risk factors on hearing as 
well as the effects of cisplatin on hearing at the base-
line assessment, to facilitate informed decision-making 
and a greater awareness of the side effects of cisplatin 
chemotherapy.
While the current study has been conducted in South 
Africa, other countries experience similar issues regard-
ing disease complexity, as reflected by the World Health 
Organization report (2018). In 2014, the World Health 
Organization indicated that one in four men and one 
in five women (i.e., 22% of the adult population aged 
18 years and older) had hypertension globally, while the 
number of people with diabetes has nearly quadrupled 
since 1980 from 108 to 422 million in 2014 [54]. Thus 
indicating that cervical cancer patients receiving cispl-
atin chemotherapy may experience an increased risk of 
hearing complications. This may be true since there is an 
increase in the prevalence of cancer patients presenting 
with other co-morbidities while receiving cisplatin treat-
ment. These current study findings bear testimony to the 
development of appropriate treatment management pro-
tocols of cisplatin related toxicities, e.g., an ototoxicity 
monitoring programme, in order to improve overall qual-
ity of life in cancer patients.
Conclusion
This study has demonstrated that this cohort of South 
African women with cervical cancer presented with 
various risk factors, such as HIV infection, diabetes, 
hypertension, ototoxic medication, and pre-existing 
hearing loss, all of which may predispose them to 
develop cisplatin hearing loss. Considering that South 
Africa is burdened with a high prevalence of both infec-
tious and NCDs, it is essential that a patient’s hearing 
is assessed before commencing cisplatin chemother-
apy. This will enable the identification of known risk 
factors in an attempt to manage the patient as well as 
accurately monitor the impact of cisplatin ototoxicity. 
Our findings revealed the presence of a clinical hearing 
loss in the absence of symptoms; mild high-frequency 
hearing loss may go unnoticed unless there is routine 
monitoring of patients before, during, and post-chem-
otherapy. Furthermore, permanent sensorineural hear-
ing loss emphasizes the need for possible referrals to 
other healthcare professionals, including psychologists 
and occupational therapists as hearing loss may impact 
on all facets of life [55]. Additionally, there is an 
increased need to counsel the patient and significant 
others, such as partners, children, and friends to facili-
tate early implementation of communication enhancing 
strategies and reduce the adverse effects on quality of 
life associated with hearing impairment [55], especially 
in light of the diagnosis of cervical cancer.
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